AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
eXoZymes, Inc.
Video analysis: EXOZ
All videosNo video analysis for this stock yet. Request one from our team.
News: EXOZ
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technology The agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful pilot-scale validation toward commercial manufacturing. Damien Perriman, Chief Commercial Officer of eXoZymes, states, "We are advancing the work required to establish the manufacturing pathway and supply chain to support NCT's planned commercial launch.
eXoZymes Q2 Earnings Call Highlights
eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter. The company, which
eXoZymes Q2 Earnings Call Highlights
eXoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.
eXoZymes (NASDAQ:EXOZ) Shares Down 1.1% – What’s Next?
eXoZymes Inc. (NASDAQ: EXOZ - Get Free Report)'s stock price dropped 1.1% on Monday. The stock traded as low as $4.60 and last traded at $4.60. Approximately 12,408 shares were traded during trading, an increase of 30% from the average session volume of 9,573 shares. The stock had previously closed at $4.65. Analyst Upgrades and
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.
